Spero Therapeutics Statistics Share Statistics Spero Therapeutics has 56.28M
shares outstanding. The number of shares has increased by 3.44%
in one year.
Shares Outstanding 56.28M Shares Change (YoY) 3.44% Shares Change (QoQ) 2.55% Owned by Institutions (%) 27.28% Shares Floating 38.58M Failed to Deliver (FTD) Shares 22,873 FTD / Avg. Volume 2.27%
Short Selling Information The latest short interest is 927.16K, so 1.65% of the outstanding
shares have been sold short.
Short Interest 927.16K Short % of Shares Out 1.65% Short % of Float 2.01% Short Ratio (days to cover) 1
Valuation Ratios The PE ratio is -0.81 and the forward
PE ratio is -53.5.
Spero Therapeutics's PEG ratio is
0.
PE Ratio -0.81 Forward PE -53.5 PS Ratio 2.03 Forward PS 403.3 PB Ratio 1.21 P/FCF Ratio -2.37 PEG Ratio 0
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Spero Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 2.19,
with a Debt / Equity ratio of 0.09.
Current Ratio 2.19 Quick Ratio 2.19 Debt / Equity 0.09 Debt / EBITDA -0.06 Debt / FCF -0.18 Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $856.13K Profits Per Employee $-2.14M Employee Count 32 Asset Turnover 0.25 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by 62.88% in the
last 52 weeks. The beta is 1.46, so Spero Therapeutics's
price volatility has been higher than the market average.
Beta 1.46 52-Week Price Change 62.88% 50-Day Moving Average 2.33 200-Day Moving Average 1.41 Relative Strength Index (RSI) 53.96 Average Volume (20 Days) 1,007,540
Income Statement In the last 12 months, Spero Therapeutics had revenue of 27.4M
and earned -68.57M
in profits. Earnings per share was -1.27.
Revenue 27.4M Gross Profit 27.39M Operating Income -73.36M Net Income -68.57M EBITDA -72.48M EBIT -72.48M Earnings Per Share (EPS) -1.27
Full Income Statement Balance Sheet The company has 52.89M in cash and 4.3M in
debt, giving a net cash position of 48.59M.
Cash & Cash Equivalents 52.89M Total Debt 4.3M Net Cash 48.59M Retained Earnings -459.64M Total Assets 62.12M Working Capital 44.46M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -23.44M
and capital expenditures 0, giving a free cash flow of -23.44M.
Operating Cash Flow -23.44M Capital Expenditures n/a Free Cash Flow -23.44M FCF Per Share -0.43
Full Cash Flow Statement Margins Gross margin is 99.99%, with operating and profit margins of -267.78% and -250.28%.
Gross Margin 99.99% Operating Margin -267.78% Pretax Margin -250.28% Profit Margin -250.28% EBITDA Margin -264.57% EBIT Margin -267.78% FCF Margin -85.57%
